We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 23

Ranbaxy loses FDA approval for two generics
  • Shook Hardy & Bacon LLP
  • India, USA
  • November 13 2014

According to a statement that Ranbaxy Laboratories Ltd. provided to the Bombay Stock Exchange Website, the U.S. Food and Drug Administration (FDA

FDA inspection finds CGMP violations at Bangalore facility
  • Shook Hardy & Bacon LLP
  • India, USA
  • June 26 2014

The U.S. Food and Drug Administration (FDA) has issued a warning letter to the president and CEO of Apotex, Inc., claiming that the agency's

EU agency will reinstate Ranbaxy’s GMP certificate
  • Shook Hardy & Bacon LLP
  • European Union, India
  • June 12 2014

The European Medicines Agency (EMA) has reportedly concluded its investigation of alleged non-compliance with good manufacturing practice (GMP) at

U.S. Trade Rep launches WTO action against India
  • Shook Hardy & Bacon LLP
  • USA, India
  • February 13 2014

U.S. Trade Representative Michael Froman has announced that the United States has requested dispute settlement consultations with India before the

India-based company’s drugs barred from U.S. market
  • Shook Hardy & Bacon LLP
  • India, USA
  • January 30 2014

The U.S. Food and Drug Administration (FDA) has prohibited imported drug products from a Ranbaxy Laboratories, Inc. facility in India due to

India to ban PET packaging for certain pharmaceuticals
  • Shook Hardy & Bacon LLP
  • India, USA
  • January 9 2014

Citing increasing concerns about potential adverse health effects, the Indian Health Ministry is reportedly considering prohibiting the use of

Indian pharma interests challenge U.S. allegations of discriminatory treatment
  • Shook Hardy & Bacon LLP
  • India, USA
  • August 29 2013

According to a news source, the Indian Pharmaceutical Alliance (IPA) has challenged U.S. allegations that India's Patent Act discriminates against

House Subcommittee considers India’s pharmaceutical patent policies
  • Shook Hardy & Bacon LLP
  • India, USA
  • July 11 2013

During a recent hearing before the Subcommittee on Commerce, Manufacturing, and Trade of the House Energy & Commerce Committee, witnesses reportedly

India holds out among countries requiring transparency in industry payments
  • Shook Hardy & Bacon LLP
  • India
  • June 20 2013

According to a news source, while many countries have instituted disclosure obligations on health-care companies, often pharmaceutical and

UK and India to fund genomics and bioinformatics tech research
  • Shook Hardy & Bacon LLP
  • United Kingdom, India
  • April 4 2013

According to the U.K.'s Biotechnology and Biological Sciences Research Council (BBSRC), up to £10 million has been jointly pledged by the council and